BioCentury
ARTICLE | Company News

Oregon Health & Science University, OncoResponse deal

February 1, 2016 8:00 AM UTC

The university’s Knight Cancer Center granted OncoResponse access to patient samples to identify potential drug targets for prostate cancer and chronic myelogenous leukemia (CML). OncoResponse will sc...